Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132395) titled 'The effects of vericiguat and henagliflozin on cardiac function and prognosis in patients with heart failure with reduced ejection fraction (HFrEF) complicated with type 2 diabetes mellitus (T2DM)' on Sept. 14.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Affiliated Hospital of Guangdong Medical University
Condition:
heart failure with reduced ejection fraction (HFrEF)
type 2 diabetes mellitus (T2DM)
Intervention:
quintuple therapy group (ACEI/ARB/ARNI + Beta-Blocker + MRA + Henagliflozin + Vericiguat) :None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First En...